VIVALIS : 2013 FINANCIAL CALENDAR VIVALIS SHARES TRANSFERRED TO COMPARTMENT B
OF NYSE EURONEXT
2013 financial calendar
VIVALIS SHARES transferred to compartment B of NYSE Euronext
Nantes (France) - 11 janvier 2010 - VIVALIS (NYSE EuroneNantes, Lyon (France)
-15 January 2013- VIVALIS (NYSE Euronext), a biopharmaceutical company, today
announces its schedule for the publication of financial information for 2013.
On December 16, 2012, VIVALIS and INTERCELL announced a proposed merger of
equals with the objective to create VALNEVA, a leading European biotechnology
company in vaccines and antibodies. This merger will create an integrated
company with a greater scale and diversification, strengthened financial
profile and complementary talent and capabilities.
Event Date * **
2012 fourth-quarter and annual revenues Thursday, 14 February 2013
Shareholders' meeting on VIVALIS-INTERCELL Merger Early March 2013
to form VALNEVA S.E.
2012 annual results Tuesday, 26 March 2013
2013 first-quarter revenues Thursday, 25 April 2013
Annual general meeting Wednesday, 19 June 2013
* Subject to modification.
** Press releases are published after market closes
Upon completion of the merger, if approved, a new financial calendar will be
circulated for the financial publications of VALNEVA S.E.
In addition, NYSE Euronext has transfered VIVALIS shares from compartment C of
the Euronext to compartment B of the Euronext. This transfer will be effective
beginning 17 January 2013.
About VIVALIS (www.vivalis.com)
Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides
innovative cell-based solutions to the biotechnology and pharmaceutical
industry for the manufacture of vaccines and recombinant proteins, and
develops monoclonal antibodies for the prevention and treatment of diseases
with unmet medical needs. Vivalis' expertise and intellectual property are
leveraged in two main areas:
1.EB66^® Cell Line
Vivalis offers research and commercial licenses for its EB66^® cell line,
derived from duck embryonic stem cells, to pharmaceutical and biotechnology
companies for the production of therapeutic and prophylactic viral vaccines,
virosomes, VLPs and recombinant proteins, including monoclonal antibodies.
Clinical trials of EB66^® produced vaccines are currently on-going in the USA
and Japan and in 2012 a vaccine produced in EB66® cells received market
approval in Japan for use in animal health. Through these programs, Vivalis
receives an upfront payment, clinical stage milestone payments along with
royalties on licensees' net sales.
a.VIVA|Screen(TM) Human Antibody Discovery Platform
Customized solutions for the discovery, development and production of rare,
fully human monoclonal antibodies are offered by Vivalis. Through these
programs, Vivalis receives payments associated with the funding of discovery
research, an upfront payment, clinical stage milestone payments along with
royalties on net sales of licensed antibodies that are commercially developed
from the use of the platform.
Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded
in 1999 by the Group Grimaud (approx. 1,700 employees), one of the worldwide
leaders in animal genetic selection. Vivalis has established more than 30
partnerships and licenses with world leaders in biopharmaceutical industry,
including Sanofi Pasteur, GlaxoSmithKline Biologicals, Transgene, Pfizer
Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck
Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC
BIOTHERAPIES and LYON BIOPOLE bio-clusters and a member of the Japanese
HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama.
Listed on Euronext Paris - Compartment C of NYSE Euronext
Reuters: VLS.PA - Bloomberg: VLS FP
Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes
This document contains forward-looking statements and comments on the
company's objectives and strategies. No guarantee can be given to any of the
events anticipated by the forward-looking statements contained in this
document, which are subject to inherent risks, including risk factors
described in the company's Document de Référence, changes in economic
conditions, the financial markets or the markets in which the company
Franck Grimaud, CEO Financial communications agency
Email: firstname.lastname@example.org Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0) 1 44 71 94 93
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: VIVALIS via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.